Four years after Roche deal, little glyco-focused biotech lands new discovery deal with Astellas

Amber Tong

Putting immuno-oncology front and center in its R&D strategy, Astellas has brought in a low-profile team to help hunt for its next wave of therapies …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Four years after Roche deal, little glyco-focused biotech lands new discovery deal with Astellas

Amber Tong

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Vertex makes money from sickle cell therapy Casgevy

Sana narrows focus again to zero in on diabetes and autoimmune disease

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

The election is Tuesday. What’s at stake for the pharma industry?

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Four years af­ter Roche deal, lit­tle gly­co-fo­cused biotech lands new dis­cov­ery deal with Astel­las

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Four years after Roche deal, little glyco-focused biotech lands new discovery deal with Astellas